MEDICLINIC INTERNATIONAL PLC financials
MEDICLINIC INTERNATIONAL PLC
2138002S5BSBIZTD5I60 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | £3.23B | £3.00B |
| Other income | £25.0M | £13.0M |
| Employee benefits expense | £1.52B | £1.45B |
| Raw materials & consumables used | £770.0M | £719.0M |
| Depreciation & amortisation | £228.0M | £217.0M |
| Operating profit (EBIT) | £280.0M | £209.0M |
| Finance costs | £74.0M | £99.0M |
| Profit before tax | £211.0M | £104.0M |
| Income tax expense | £41.0M | £25.0M |
| Profit for the year | £170.0M | £79.0M |
| — attributable to owners | £151.0M | £68.0M |
| — attributable to NCI | £19.0M | £11.0M |
| Total comprehensive income | £288.0M | -£29.0M |
| Per share | ||
| Basic EPS | £0.20 | £0.09 |
| Diluted EPS | £0.20 | £0.09 |
| Cash flow statement | ||
| Cash generated from operations | £663.0M | £330.0M |
| Net cash from operating activities | £554.0M | £235.0M |
| Net cash from investing activities | -£189.0M | -£137.0M |
| Net cash from financing activities | -£149.0M | -£130.0M |
| Dividends paid | £12.0M | £8.0M |
| Proceeds from borrowings | £89.0M | £115.0M |
| Repayments of borrowings | £183.0M | £196.0M |
| Lease liability payments | £42.0M | £39.0M |
| Net change in cash | £216.0M | -£32.0M |
| Balance sheet | ||
| Total assets | £7.21B | £6.67B |
| Non-current assets | £5.73B | £5.44B |
| Property, plant & equipment | £4.38B | £4.05B |
| Intangible assets & goodwill | £1.13B | £1.06B |
| Current assets | £1.47B | £1.23B |
| Inventories | £97.0M | £109.0M |
| Trade & other receivables | £834.0M | £826.0M |
| Cash & equivalents | £534.0M | £294.0M |
| Total equity | £3.25B | £2.97B |
| — attributable to owners | £3.11B | £2.85B |
| Non-controlling interests | £139.0M | £118.0M |
| Non-current liabilities | £3.14B | £3.02B |
| Long-term borrowings | £1.69B | £1.69B |
| Lease liabilities (non-current) | £730.0M | £621.0M |
| Current liabilities | £823.0M | £684.0M |
| Short-term borrowings | £115.0M | £91.0M |
| Lease liabilities (current) | £56.0M | £55.0M |
| Trade & other payables | £586.0M | £498.0M |
| Deferred tax liabilities | £432.0M | £425.0M |
| Derived metrics | ||
| Operating margin | 8.7% | 7.0% |
| Net margin | 5.3% | 2.6% |
| Return on equity | 5.2% | 2.7% |
| Cash conversion ratio | 3.26× | 2.97× |
| Other reported items | ||
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £0 | £4.0M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £7.0M | £2.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | £30.0M | £16.0M |
| Comprehensive Income Attributable To Owners of Parent | £258.0M | -£45.0M |
| Current Derivative Financial Liabilities | £1.0M | £2.0M |
| Current Loans and Receivables | £6.0M | £2.0M |
| Current Provisions | £38.0M | £19.0M |
| Current Recognised Liabilities Defined Benefit Plan | £20.0M | £14.0M |
| Current Tax Assets | £3.0M | £1.0M |
| Current Tax Liabilities | £7.0M | £5.0M |
| Deferred Tax Assets | £32.0M | £34.0M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | £0 | £0 |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | £12.0M | £8.0M |
| Dividends Received From Investments Accounted For Using Equity Method Classified As Investing Activities | £2.0M | £0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | £24.0M | -£3.0M |
| Equity and Liabilities | £7.21B | £6.67B |
| Finance Income | £6.0M | £4.0M |
| Gains Losses On Exchange Differences On Translation Net of Tax | £182.0M | -£235.0M |
| Impairment Loss Recognised In Profit Or Loss Intangible Assets and Goodwill | £0 | £1.0M |
| Impairment Loss Recognised In Profit Or Loss Property Plant and Equipment | £7.0M | £3.0M |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | £2.0M | £0 |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | -£16.0M | £26.0M |
| Income Taxes Paid Refund Classified As Operating Activities | £46.0M | £29.0M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | £2.0M | £1.0M |
| Increase Decrease Through Sharebased Payment Transactions | £1.0M | £0 |
| Interest Paid Classified As Operating Activities | £69.0M | £70.0M |
| Interest Received Classified As Operating Activities | £6.0M | £4.0M |
| Investment Accounted For Using Equity Method | £165.0M | £171.0M |
| Issued Capital | £74.0M | £74.0M |
| Liabilities | £3.96B | £3.71B |
| Liabilities From Sharebased Payment Transactions2011 | £4.0M | £1.0M |
| Noncurrent Derivative Financial Liabilities | £128.0M | £124.0M |
| Noncurrent Provisions | £37.0M | £37.0M |
| Noncurrent Recognised Assets Defined Benefit Plan | £1.0M | £110.0M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | £119.0M | £127.0M |
| Other Comprehensive Income | £118.0M | -£108.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -£90.0M | £153.0M |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | £4.0M | £0 |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | £188.0M | -£235.0M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -£70.0M | £127.0M |
| Other Gains Losses | -£3.0M | £2.0M |
| Other Reserves | -£2.25B | -£2.44B |
| Proceeds From Changes In Ownership Interests In Subsidiaries | £2.0M | £1.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | £1.0M | £0 |
| Purchase of Interests In Associates | £0 | £1.0M |
| Retained Earnings | £4.60B | £4.52B |
| Services Expense | £169.0M | £147.0M |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted For Using Equity Method That Will Be Reclassified To Profit Or Loss Net of Tax | £1.0M | £0 |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -£1.0M | -£70.0M |
| Share Premium | £690.0M | £690.0M |
Every line item above is a fact tagged in MEDICLINIC INTERNATIONAL PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.